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The Katholiek substrain of Brown Norway (BN/Kat) rats exhibits a very low level of circulating high-molecular-mass 
(HMW) kininogen and a partial deficiency in plasma prekallikrein. Northern blot analysis of liver RNA revealed that 
HMW kininogen and prekallikrein mRNAs are present in these rats with a similar size and abundance compared to 
control Brown Norway (BN/Orl) rats. The low-molecular-mass kininogen mRNA, encoded by the same kininogen gene 
as HMW kininogen mRNA by alternative splicing, is detected in both strains by dideoxynucleotide limited primer exten- 
sion analysis. Measurement of HMW kininogen by radioimmunoassay was performed in liver subcellular fractions. It 
reveals that, in contrast to its absence in the cytosolic fraction, HMW kininogen in deficients rats is slightly more abun- 
dant in the microsomal fraction, than in control rats. These observations exclude both an abnormality at the level of 
gene transcription and a major structural modification of the transcribed RNA and of the synthesized HMW kininogen. 
They favour the hypothesis of an abnormal intracellular transport of the HMW kininogen in deficient rats. 
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1. INTRODUCTION 
Kininogens are multifunctional multidomain 
proteins containing the sequence of bradykinin in 
their molecule. They are synthesized in the liver 
and circulate in plasma. 
In most mammals, there are two different forms 
of kininogen: the high-molecular-mass (HMW) 
kininogen and the low-molecular-mass (LMW) 
kininogen, which differ in molecular size, sensitivi- 
ty to kallikreins and physiological functions [I]. 
The HMW and LMW kininogens are single 
chain glycoproteins, consisting of three functional 
domains: an amino-terminal domain, called ‘heavy 
chain’, the bradykinin moiety released during pro- 
teolysis by kallikreins and a carboxyl-terminal do- 
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main, called ‘light chain’. This last domain is of a 
reduced size in LMW kininogen, but in HMW 
kininogen it represents a large polypeptide chain 
responsible for the coagulation promoting activity 
of this molecule. The first and third domains are 
bound by a disulfide bridge. 
HMW and LMW kininogen mRNAs in the rat 
are identical in nucleotide sequence up to the first 
35 nucleotides residues of the light chains, after 
which their sequences differ completely. In fact, 
they are encoded from a single gene, the K 
kininogen gene bearing 11 exons. Part of the 10th 
and the 11 th exons code for the specific sequences 
of HMW and LMW kininogen mRNAs, respec- 
tively [2]. Differential use of the two 3’-terminal 
exons is responsible for the generation of the two 
forms of kininogen mRNAs through alternative 
splicing of the gene transcript [12]. 
In the rat, in addition to HMW and LMW 
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kininogens, there are two other low-molecular- 
mass kininogen species: T-kininogen I and II, 
which are not substrates for kallikreins. The T-I 
and T-II kininogen mRNAs are highly 
homologous to LMW kininogen (around 9OYo) [3]. 
They are generated from two other closely related 
but distinct genes (T-I and T-II kininogen genes). 
Rare inherited deficiencies in HMW kininogen 
have been reported in man, associated with pro- 
longed partial thromboplastic time and defective 
release in vitro of plasma kinins [4-61. In the rat, 
a Brown Norway substrain (BN/Kat), bred in the 
Katholiek University of Leuven (Belgium), has 
been reported to be congenitally deficient in 
plasma HMW kininogen and unable to release 
kinins when treated with contact activating agents 
[7]. These animals have undetectable levels of im- 
munoreactive HMW kininogen by crossed im- 
munoelectrophoresis and their HMW kininogen 
concentration determined by a direct radioim- 
munoassay is less than 2% of the normal strain 
[8,18]. Like humans with HMW kininogen defi- 
ciency, these rats display coagulation abnor- 
malities. They also exhibit reduced reactivity to 
inflammatory stimuli. Finally, they have been 
reported to also show a reduced plasma 
prekallikrein concentration [9]. 
In the present study, we analyzed transcription 
products of HMW kininogen, LMW kininogen 
and prekallikrein genes in BN/Kat compared with 
the control strain BN/Orl. Unexpectedly, HMW 
kininogen mRNA was detected at normal levels in 
the deficient rats. Immunoreactive HMW 
kininogen was studied in plasma and in liver 
subcellular fractions by direct radioimmunoassay 
(RIA). 
2. MATERIALS AND METHODS 
2.1. Animals 
The two substrains of Brown Norway rats used were bred in 
our laboratory [S]: BN/Kat, deficient Brown Norway rats, 
from animals kindly supplied by Dr J. Damas, and originating 
from the inbred substrain of the Katholiek University of Leuven 
(Belgium) [7]; BN/Orl, normal Brown Norway rats, from a 
substrain originating in Orleans (France). Eight-week-old 
female rats were used. 
2.2. Northern blot 
2.2.1. RNA preparation 
Livers were removed from anesthetized rats, immediately 
frozen in liquid nitrogen, and then stored at -70°C. Total 
60 
RNA was extracted by the guanidine-cesium chloride method 
[lo]. Total RNA concentration was determined by measure- 
ment of optical density at 260 nm. 
2.2.2. Oligonucleotide and cDNA probes 
Two different oligonucleotides were synthesized (fig.1): LK is 
a 38-mer complementary to nucleotides 1194-1231 common to 
the three low-molecular-mass kininogen mRNA species (K, TI, 
Tz) [ll]. HK is a 50-mer, corresponding to nucleotides 
1848-1899 [12] of the HMW kininogen mRNA and is specific 
to this RNA species. The LK oligonucleotide was radioactively 
labelled at its 5 ‘-ends with [y-32P]ATP using T4 polynucleotide 
kinase. A DNA complementary to HK oligonucleotide was syn- 
thesized with [a-32P]dCTP and the Klenow enzyme, using a 
12-mer complementary to the 3 ‘-end of HK as a primer. Rat 
liver prekallikrein cDNA (Seidah et al., in preparation) was 
labelled using the random primer DNA labelling reaction [13] 
and [cu-32P]dCTP. 
2.2.3. Northern blot analysis , 
Northern blots were performed with glyoxalated RNA, ac- 
cording to the method of P. Thomas 1141. Hybridization of the 
blots with the different 32P-labelled kininogen oligonucleotide 
and kallikrein cDNA probes was done at 42°C in 50% for- 
mamide for 24 h. The blots were then washed at 50°C in 0.1 x 
SSC, 0.1% NaDodSOd (1 x SSC is 0.15 M NaCI, 15 mM 
sodium citrate, pH 7.0). 
RNA transfer was checked by hybridization with a rat actin 
cDNA fragment. 
2.3. Dideoxynucleotide limited primer extension analysis 
In this procedure, in order to specifically distinguish between 
highly homologous LMW and T-kininogen mRNAs, we took 
advantage of base differences existing in the different 
transcripts for kininogens upstream from the sequence com- 
plementary to the LK oligonucleotide. Poly(A) mRNA (10 rg) 
was hybridized with 9 x 10’ cpm of the labelled LK primer 
(specific activity: 4 x 10’ cpm/pg). Primer extension was per- 
formed according to L.J. Field [15], using 29 units of AMV 
reverse transcriptase (Stehlin, Basel, Switzerland) and dide- 
oxyATP. Samples were analyzed on 6% acrylamide/‘l M urea 
sequencing el. 
2.4. Western blot 
Plasma proteins were analyzed after reduction (5% 
2-mercaptoethanol) and denaturation (3 min boiling) by elec- 
trophoresis in 8% polyacrylamide gel containing NaDodS04, 
according to the method of Laemmli [16]. Proteins were then 
transferred electrophoretically to nitrocellulose [17]. The blot 
was incubated for 12 hat 4°C with an anti-HMW kininogen an- 
tiserum [18] and then for 30 min at room temperature with a 
goat antirabbit immunoglobulin antibody conjugated to 
alkaline-phosphatase, and stained using the Protoblot system 
(Promega-Biotec, Madison, USA). 
2.5. Tissue fractionation 
Three BN/Orl and three BN/Kat rats were fasted for 12 h 
before the experiment. After collecting blood under ether 
anesthesia, livers were perfused with 80 ml of 0.9% NaCI, 
removed and immersed in a homogenization solution (20 mM 
Tris, pH 7.5/5 mM MgC12/0.25 M saccharose) containing a 
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protease inhibitor mixture (10 mg/ml phenylmethanesulfonyl 
fluoride, 1000 U/ml Trasylol and 10 mg/ml pepstatin A). 
Tissue fractionation studies were performed according to the 
procedure of De Duve [19]. Three fractions were separated: 
whole tissue homogenate, microsomal fraction and final super- 
natant (cytosoluble fraction). After Potter homogenization 
(2000 rpm), the homogenate was centrifuged at 13300 x g at 
4°C for 15 min and the pellet discarded. After taking an aliquot 
(homogenate fraction), the supernatant was centrifuged again 
at 100000 x g for 1 h and collected (cytosoluble fraction). The 
pellet was then resuspended in the same buffer and submitted 
to an identical centrifugation. The final pellet (microsomal frac- 
tion) was resuspended in 20 mM Tris, pH 7.5/5 mM EDTA 
with the protease inhibitor mixture. After adding Chaps to 
0.1% in order to solubilize proteins trapped in the membrane, 
all samples were stored at -8O”C, until assayed. HMW 
kininogen was measured by RIA in all these fractions and in 
plasma. Protein content of all 3 fractions was quantified by the 
method of Lowry [20] using BSA as a standard. 
2.6. Radioimmunoassay 
The HMW kininogen was assayed by direct RIA, as previous- 
ly described [18]. Antibodies raised against HMW kininogen 
did not display detectable levels of cross-reactivity with T 
kininogens in this RIA 1181. 
3. RESULTS AND DISCUSSION 
The deficiency in HMW kininogen in BN/Kat is 
due to a genetic abnormality which may be located 
on either the regulatory or the structural part of 
the gene. Northern blot experiments of normal and 
deficient BN rats revealed the presence of HMW 
and low-molecular-mass kininogen mRNAs in the 
two strains of rats (fig. 1). The HK synthetic probe, 
which corresponds to a sequence located inside the 
light chain specific to the HMW kininogen, 
hybridized with a single 2.2 kb RNA species, cor- 
responding to that described by Kageyama et al. 
[21] for rat HMW kininogen. The HMW 
kininogen mRNA in both BN/Orl and BN/Kat has 
a similar size and is detected in similar amount. 
The LK probe, which has a sequence common to 
the three low-molecular-mass kininogen mRNA 
species but not present in HMW kininogen mRNA 
hybridized with a mRNA of lower size (1.6 kb) 
corresponding to the three low-molecular-mass 
kininogen mRNA species, Ti, T2 and LMW. The 
band corresponding to these RNAs is equally pre- 
sent on Northern blot in the two BN strains. 
The lack of regions showing sufficient base dif- 
ferences between the light chains of T kininogens 
and LMW kininogen gene transcripts precluded 
the preparation of gene specific hybridization 
probes, thus we used the dideoxynucleotide limited 
Fig. 1. (Upper panel) Northern blot hybridization of 20 pg total 
liver RNA with HK, LK and prekallikrein cDNA probes. 
(Lower panel) Schematic localization of the oligonucleotide 
probes: HK probe (50 bases) and LK probe (38 bases) are 
indicated on the structure of HMW and LMW kininogen (Kg) 
mRNA, respectively. Hatched and solid boxes represent he 
signal peptide and the bradykinin sequence, respectively. The 
arrows indicate the beginning of the light chain of both 
kininogens. 
primer extension analysis to investigate the specific 
presence of LMW kininogen mRNA. A base pair 
difference is located six bases upstream from the 
3’-end of the LK primer on the mRNAs, with an 
adenine residue in the two T kininogen transcripts 
whereas there is a uracyl residue in the LMW 
kininogen transcript. The next uracyl residue is 
located 9 bases further upstream and is present in 
all three transcripts (see fig.2). The results of 
primer extension are shown in fig.2. A 44-base and 
a 53-base fragment were generated in the two 
strains showing that both the T kininogens and the 
LMW kininogen mRNAs were present in BN/Kat 
and BN/Orl rats. 
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Fig.2. Dideoxynucleotide limited primer extension analysis of 
LMW kininogen transcripts of BN/Kat (1) and BN/Orl(2) rats. 
A sequence reaction was used as size marker. LK represents the 
non-extended 38 base oligomer used as primer, L band (44 
bases) and T band (53 bases) correspond to fragments generated 
during primer extension by LMW and T kininogen mRNAs, 
respectively. 
Damas previously reported that BN/Kat rats 
were also deficient in plasma prekallikrein [7] but 
later observed that their prekallikrein plasma levels 
were 2530% of normal rats [9]. A deficiency in 
circulating prekallikrein could affect the stability 
of kininogen in plasma, as prekallikrein and HMW 
kininogen together form a circulating complex. We 
have investigated the presence of prekallikrein 
mRNA in the liver of the two BN strains by Nor- 
thern hybridization using a rat prekallikrein 
cDNA. Fig.1 shows that a prekallikrein transcript 
is present in the BN/Kat and the BN/Orl strains, 
and has the same size and abundance in both 
strains. 
Thus, in agreement with a recent study publish- 
ed by Fung et al. [22] at the time this work was be- 
ing completed, transcription of HMW kininogen 
mRNA occurs in the BN deficient rats as well as in 
the non-deficient BN animals. This observation ex- 
cludes the occurrence of an abnormality in the 
level of transcription as well as a major structural 
modification of the transcribed RNA. The LMW 
kininogen and liver kallikrein transcripts are also 
generated normally in both strains. These results 
prompted us to investigate further the presence 
and the structure of the HMW kininogen mRNA 
translation product. 
The Western-blot technique was used to detect 
kininogen in plasma using a rat HMW kininogen 
antiserum. In BN/Orl plasma samples (fig.3), a 
major band, 120 kDa in size, was present, cor- 
responding to the HMW kininogen. BN/Kat defi- 
ciency in plasma HMW kininogen was confirmed, 
although a very weak HMW kininogen band was 
detected. 
HMW kininogen content of plasma and liver ex- 
tracts was also measured by RIA (table 1). In con- 
trast to the almost complete absence of 
immunoreactive HMW kininogen in plasma of 
BN/Kat, the HMW kininogen content in whole 
liver homogenate of BN/Kat was two-thirds that 
found in BN/Orl liver homogenate. We found that 
the RIA dilution curves of liver HMW kininogen 
was parallel to the standard curve obtained with 
pure Wistar rat HMW kininogen in both species 
(not shown). Therefore, the liver HMW kininogen 
appeared immunologically identical in BN/Kat rat 
to the HMW kininogen of other rats. 
HMW kininogen content was also measured 
in microsomal and cytosolic fractions. In 
microsomes, HMW kininogen content was slightly 
higher in BN/Kat than in BN/Orl. However, 
HMW kininogen does not seem to accumulate in 
this compartment in either strain, since no enrich- 
ment is observed in comparison to the whole 
cellular homogenate. These observations, together 
with that of the presence of a lower amount of 
HMW kininogen in the cytosoluble fraction of 
BN/Kat rats in comparison to BN/Orl animals 
(table l), is in favour of an abnormal intracellular 
traffic of the HMW kininogen in BN/Kat rats. 
The presence of a very low amount of im- 
munoreactive HMW kininogen in BN/Kat plasma, 
by RIA, confirmed by the result of Western blot, 
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Fig.3. Western blot analysis of plasma HMW kininogen. A 
HMW kininogen antiserum was used for immunodetection. 
Two plasma concentrations of BN/Orl (0) and of BN/Kat (K) 
rats were applied on the gel (lane 1: 8Opg, lane 2: 400 yg 
protein). 
strengthens the hypothesis that HMW kininogen 
deficiency is more likely due to an altered exporta- 
tion than to a major structural modification of the 
protein. 
Specific measurement of LMW kininogen in rat 
plasma is not possible due to the lack of specific 
antibodies to this kininogen species. A previous 
study reported that the BN/Kat rats were deficient 
in LMW kininogen [23]. However, results obtain- 
ed in this laboratory indicate that the plasma of 
Table 1 
Liver tissue fractionation study: immunoreactive HMW- 
kininogen in subcellular fractions and plasma of normal 
(BN/Orl) and deficient (BN/Kat) Brown Norway rats 
HMW kininogen concentrations 
Rat number BN/Orl BN/Kat 
Homogenate 1 114.0 82.0 
(ng/mg prot.) 2 136.9 82.9 
3 109.5 87.2 
Microsomes 1 49.7 96.2 
(ng/mg prot.) 2 96.3 100.0 
3 52.5 96.2 
Cytosol 1 92.4 8.5 
(ng/mg prot.) 2 111.8 7.7 
3 103.3 7.8 
Plasma 1 51 1.8 
(mgjml) 2 46 1.5 
3 46 1.7 
Values are expressed as ng/mg protein in each subfraction. 
Results obtained for 3 different animals in each substrain are 
given (rat number is indicated for each value) 
these animals is able to generate bradykinin upon 
treatment with rat urinary kallikrein and therefore 
contains a kallikrein sensitive kininogen. 
Moreover, the BN/Kat rats excrete normal levels 
of kinins in urine. These kinins most likely 
originating from a kallikrein sensitive kininogen 
detected in urine also in normal animals (Baussant, 
T. et al., in preparation). This kininogen is prob- 
ably the LMW kininogen. These observations 
taken together suggest that the kininogen gene en- 
coding for HMW and LMW kininogen could pre- 
sent a structural abnormality located after the 
region coding for bradykinin. The gene defect 
could be tentatively localized to the HMW 
kininogen specific exon 10. As this exon is also im- 
plicated in the formation of the complex with 
plasma prekallikrein, the observed partial deficien- 
cy in plasma prekallikrein could be due, at least in 
part, to the reduced stability in the circulation of 
the prekallikrein molecule not complexed to HMW 
kininogen. 
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